ArticleeLife2020
Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism.
Abstract read
In one paragraph
Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Unraveling Activation-Related Rearrangements and Intrinsic Divergence from Ligand-Specific Conformational Changes of the Dopamine D3 and D2 Receptors.Journal of chemical information and modeling · 2024Review
- Unraveling activation-related rearrangements and intrinsic divergence from ligand-induced conformational changes of the dopamine D3 and D2 receptors.bioRxiv : the preprint server for biology · 2023Article
- Subtle Structural Modification of a Synthetic Cannabinoid Receptor Agonist Drastically Increases its Efficacy at the CB1 Receptor.ACS chemical neuroscience · 2023Article
- A Novel "Activation Switch" Motif Common to All Aminergic Receptors.Journal of chemical information and modeling · 2023Review
- The Molecular Mechanism of Positive Allosteric Modulation at the Dopamine D1 Receptor.International journal of molecular sciences · 2023Article
- The molecular mechanism of positive allosteric modulation at the dopamine D1 receptor.bioRxiv : the preprint server for biology · 2023Article
- Unveiling the Differences in Signaling and Regulatory Mechanisms between Dopamine DInternational journal of molecular sciences · 2023Review
- Binding preference at the μ-opioid receptor underlies distinct pharmacology of cyclopropyl versus valeryl analogs of fentanyl.Neuropharmacology · 2023Article
- Unique effect of clozapine on adenosine ABiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Article
- Comparative evaluation of biased agonists SarcosinePharmacology research & perspectives · 2023Article
- Identification and Characterization of ML321: A Novel and Highly Selective DACS pharmacology & translational science · 2023Article
- An original approach to measure ligand/receptor binding affinity in non-purified samples.Scientific reports · 2022Article
- A comprehensive evaluation of the potential binding poses of fentanyl and its analogs at the µ-opioid receptor.Computational and structural biotechnology journal · 2022Article
- Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine DFrontiers in psychiatry · 2022Review
- Evidence for Two Modes of Binding of the Negative Allosteric Modulator SB269,652 to the Dopamine DBiomedicines · 2021Article
- Recent Advances in Structure, Function, and Pharmacology of Class A Lipid GPCRs: Opportunities and Challenges for Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Chiral Cyclic Aliphatic Linkers as Building Blocks for Selective Dopamine DJournal of medicinal chemistry · 2021Article
- Structure Activity Relationships for a Series of Eticlopride-Based Dopamine DJournal of medicinal chemistry · 2021Article
- Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the DMolecular pharmacology · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
J Robert LaneDivision of Pharmacology, Physiology and Neuroscience, School of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham, United Kingdom.
Ara M AbramyanComputational Chemistry and Molecular Biophysics Unit, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, Baltimore, United States.
Pramisha AdhikariComputational Chemistry and Molecular Biophysics Unit, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, Baltimore, United States.
Alastair C KeenDivision of Pharmacology, Physiology and Neuroscience, School of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham, United Kingdom.
Kuo-Hao LeeComputational Chemistry and Molecular Biophysics Unit, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, Baltimore, United States.
Julie SanchezDivision of Pharmacology, Physiology and Neuroscience, School of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham, United Kingdom.
Ravi Kumar VermaComputational Chemistry and Molecular Biophysics Unit, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, Baltimore, United States.
Herman D LimDrug Discovery Biology, Department of Pharmacology and Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia.
Hideaki YanoComputational Chemistry and Molecular Biophysics Unit, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, Baltimore, United States.
Jonathan A JavitchDepartment of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York, United States.
Lei ShiComputational Chemistry and Molecular Biophysics Unit, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, Baltimore, United States.ORCID 0000-0002-4137-096X
Funding
Structural basis for the functions of dopamine receptors, neurotransmitter transporters, and sigma 1 receptorZIADA000606 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI SHI, LEI · 2015 to 2025
$20.5MStructure of the Dopamine D2-Like Receptor Binding SitesR01MH054137 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI JAVITCH, JONATHAN A · 1995 to 2025
$12.0MIntramural NIH HHS ZIA DA000606NIH HHS MH54137NIMH NIH HHS R01 MH054137
Abstract
By analyzing and simulating inactive conformations of the highly homologous dopamine D
Indexed as
Dopamine AgonistsDopamine AntagonistsReceptors, Dopamine D2Receptors, Dopamine D3Binding SitesDrug DiscoveryMolecular Dynamics SimulationProtein BindingProtein ConformationRisperidoneSalicylamidesDopamine AgonistsDopamine AntagonistseticloprideReceptors, Dopamine D2Receptors, Dopamine D3RisperidoneSalicylamidesbiochemistrychemical biologydopamine d2 receptorinverse agonismmolecular biophysicsmolecular dynamicsna+ sensitivitynonestructural biology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC0
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.